Cargando…

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion

BACKGROUND: Urokinase plasminogen activator (uPA) receptor (uPAR) is up-regulated at the invasive tumour front of human oral squamous cell carcinoma (OSCC), indicating a role for uPAR in tumour progression. We previously observed elevated expression of uPAR at the tumour-stroma interface in a mouse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magnussen, Synnove Norvoll, Hadler-Olsen, Elin, Costea, Daniela Elena, Berg, Eli, Jacobsen, Cristiane Cavalcanti, Mortensen, Bente, Salo, Tuula, Martinez-Zubiaurre, Inigo, Winberg, Jan-Olof, Uhlin-Hansen, Lars, Svineng, Gunbjorg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438506/ https://www.ncbi.nlm.nih.gov/pubmed/28526008 http://dx.doi.org/10.1186/s12885-017-3349-7

Ejemplares similares

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Nephronectin as a Matrix Effector in Cancer
por: Magnussen, Synnøve Norvoll, et al.
Publicado: (2021)

Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma
por: Rikardsen, Oddveig G., et al.
Publicado: (2015)

The effect of interleukin‐17F on vasculogenic mimicry in oral tongue squamous cell carcinoma
por: Almahmoudi, Rabeia, et al.
Publicado: (2021)

Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts
por: Hadler-Olsen, Elin, et al.
Publicado: (2010)

Nephronectin promotes breast cancer brain metastatic colonization via its integrin-binding domains
por: Magnussen, Synnøve Norvoll, et al.
Publicado: (2020)

Nephronectin mediates p38 MAPK‐induced cell viability via its integrin‐binding enhancer motif
por: Toraskar, Jimita, et al.
Publicado: (2018)

The interplay of matrix metalloproteinase-8, transforming growth factor-β1 and vascular endothelial growth factor-C cooperatively contributes to the aggressiveness of oral tongue squamous cell carcinoma
por: Åström, Pirjo, et al.
Publicado: (2017)

Tumour cells express functional lymphatic endothelium-specific hyaluronan receptor in vitro and in vivo: Lymphatic mimicry promotes oral oncogenesis?
por: Karinen, Sini, et al.
Publicado: (2021)

Validation of Selected Head and Neck Cancer Prognostic Markers from the Pathology Atlas in an Oral Tongue Cancer Cohort
por: Wirsing, Anna Maria, et al.
Publicado: (2021)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

Molecular Interactions Stabilizing the Promatrix Metalloprotease-9·Serglycin Heteromer
por: Dawadi, Rangita, et al.
Publicado: (2020)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
por: Shmakova, Anna A., et al.
Publicado: (2022)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma
por: Semina, Ekaterina V., et al.
Publicado: (2020)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)

The proteoglycan repertoire of lymphoid cells
por: Fadnes, Bodil, et al.
Publicado: (2012)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
por: Sharma, Shailza, et al.
Publicado: (2021)

The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases
por: Sylte, Ingebrigt, et al.
Publicado: (2018)

The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells
por: Lejeune, Danielle, et al.
Publicado: (2006)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
por: Mauro, Concetta Di, et al.
Publicado: (2017)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
por: Harel, Efrat T., et al.
Publicado: (2019)

Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR–β1 integrin complex in colon cancer cells
por: Ahmed, N, et al.
Publicado: (2003)

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
por: Margheri, Francesca, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives
por: Skovgaard, Dorthe, et al.
Publicado: (2016)

Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
por: Alpízar-Alpízar, Warner, et al.
Publicado: (2020)

Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs
por: Chang, Yu-Ching, et al.
Publicado: (2023)

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer
por: Illemann, Martin, et al.
Publicado: (2014)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
por: Zhao, Baoyu, et al.
Publicado: (2015)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
por: Christensen, Anders, et al.
Publicado: (2017)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_b5k0i66dva9d33qhjhi76hrru2